BACKGROUND/AIMS: Antagonism of the endocannabinoid receptor-1 (CB1R) directly improves whole-body metabolic parameters of insulin resistance. The present investigation determined the effects of chronic CB1R antagonism on whole-body and skeletal-muscle insulin action in insulin-sensitive lean and insulin-resistant obese Zucker rats. METHODS: Animals were either fed ad libitum or in pairs, or treated with SR141716 (10 mg/kg i.p. for 14 days). RESULTS: Food intake was significantly reduced (p < 0.05) after initial SR141716 treatment and remained decreased in both lean and obese animals until day 13. Fasting plasma glucose decreased (24%) and insulin increased (43%) in lean SR141716-treated (24%) rats compared to lean ad libitum-fed controls, but not in the corresponding obese groups. Fasting plasma free fatty acids were reduced by CB1R antagonism in lean (21%) and obese (42%) animals. Whole-body insulin sensitivity was increased (36%) in obese SR141716-treated rats compared to obese ad libitum-fed controls, which was associated with reduced insulin secretion during an oral glucose tolerance test. Insulin-stimulated glucose transport activity in the soleus was greatest in the respective SR141716-treated lean and obese groups compared to the corresponding ad libitum- and pair-fed controls. Chronic SR141716 treatment did not induce alterations in signaling factors associated with the regulation of glucose transport [protein kinase B (Akt), glycogen synthase kinase-3β, 5'-AMP-dependent protein kinase, or p38 mitogen-activated protein kinase] in the soleus. CONCLUSIONS: These results indicate that, while the chronic treatment with CB1R antagonism markedly diminished food intake in lean and obese Zucker rats, there are also significant metabolic improvements in whole-body and skeletal-muscle insulin action mediated by CB1R antagonism through mechanisms independent of reduced caloric intake.
BACKGROUND/AIMS: Antagonism of the endocannabinoid receptor-1 (CB1R) directly improves whole-body metabolic parameters of insulin resistance. The present investigation determined the effects of chronic CB1R antagonism on whole-body and skeletal-muscle insulin action in insulin-sensitive lean and insulin-resistant obese Zucker rats. METHODS: Animals were either fed ad libitum or in pairs, or treated with SR141716 (10 mg/kg i.p. for 14 days). RESULTS: Food intake was significantly reduced (p < 0.05) after initial SR141716 treatment and remained decreased in both lean and obese animals until day 13. Fasting plasma glucose decreased (24%) and insulin increased (43%) in lean SR141716-treated (24%) rats compared to lean ad libitum-fed controls, but not in the corresponding obese groups. Fasting plasma free fatty acids were reduced by CB1R antagonism in lean (21%) and obese (42%) animals. Whole-body insulin sensitivity was increased (36%) in obeseSR141716-treated rats compared to obese ad libitum-fed controls, which was associated with reduced insulin secretion during an oral glucose tolerance test. Insulin-stimulated glucose transport activity in the soleus was greatest in the respective SR141716-treated lean and obese groups compared to the corresponding ad libitum- and pair-fed controls. Chronic SR141716 treatment did not induce alterations in signaling factors associated with the regulation of glucose transport [protein kinase B (Akt), glycogen synthase kinase-3β, 5'-AMP-dependent protein kinase, or p38 mitogen-activated protein kinase] in the soleus. CONCLUSIONS: These results indicate that, while the chronic treatment with CB1R antagonism markedly diminished food intake in lean and obese Zucker rats, there are also significant metabolic improvements in whole-body and skeletal-muscle insulin action mediated by CB1R antagonism through mechanisms independent of reduced caloric intake.
Authors: S Xie; M A Furjanic; J J Ferrara; N R McAndrew; E L Ardino; A Ngondara; Y Bernstein; K J Thomas; E Kim; J M Walker; S Nagar; S J Ward; R B Raffa Journal: J Clin Pharm Ther Date: 2007-06 Impact factor: 2.512
Authors: Francisco Javier Bermúdez-Siva; Antonia Serrano; Francisco Javier Diaz-Molina; Irene Sánchez Vera; Pablo Juan-Pico; Angel Nadal; Esther Fuentes; Fernando Rodríguez de Fonseca Journal: Eur J Pharmacol Date: 2006-01-19 Impact factor: 4.432
Authors: A Dresner; D Laurent; M Marcucci; M E Griffin; S Dufour; G W Cline; L A Slezak; D K Andersen; R S Hundal; D L Rothman; K F Petersen; G I Shulman Journal: J Clin Invest Date: 1999-01 Impact factor: 14.808
Authors: Mauro Maccarrone; Itai Bab; Tamás Bíró; Guy A Cabral; Sudhansu K Dey; Vincenzo Di Marzo; Justin C Konje; George Kunos; Raphael Mechoulam; Pal Pacher; Keith A Sharkey; Andreas Zimmer Journal: Trends Pharmacol Sci Date: 2015-03-18 Impact factor: 14.819
Authors: Isabel González-Mariscal; Rodrigo A Montoro; Jennifer F O'Connell; Yoo Kim; Marta Gonzalez-Freire; Qing-Rong Liu; Irene Alfaras; Olga D Carlson; Elin Lehrmann; Yongqing Zhang; Kevin G Becker; Stéphan Hardivillé; Paritosh Ghosh; Josephine M Egan Journal: FASEB J Date: 2019-02-06 Impact factor: 5.834
Authors: Hannah Lees; Jonathan Swann; Simon M Poucher; Jeremy K Nicholson; Elaine Holmes; Ian D Wilson; Julian R Marchesi Journal: PLoS One Date: 2014-09-18 Impact factor: 3.240
Authors: Cherno O Sidibeh; Maria J Pereira; Joey Lau Börjesson; Prasad G Kamble; Stanko Skrtic; Petros Katsogiannos; Magnus Sundbom; Maria K Svensson; Jan W Eriksson Journal: Endocrine Date: 2016-11-17 Impact factor: 3.633